Sigilon Therapeutics (SGTX) has filed to raise $101 million from the sale of its common stock in an IPO, according to an amended registration statement. Cambridge, Massachusetts-based Sigilon was ...
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shield ...
Eli Lilly and Sigilon Therapeutics have announced a collaboration to develop therapies based around capsules of genetically-engineered stem cells to treat type 1 diabetes. A privately-held biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback